BIOPOR - Bioporto A/S News Story
DKK5.21 -0.2 -3.0%
Last Trade - 3:59pm
| Market Cap | £167.6m |
| Enterprise Value | £156.3m |
| Revenue | £2.71m |
| Position in Universe | 759th / 1830 |
BRIEF-Bioporto Says Expects To Complete Clinical Study And Submit A De Novo Application To FDA For Pediatric Use Of NGAL Test This Summer
Wed 3rd March, 2021 5:47pm
March 3 (Reuters) - Bioporto A/S BIOPOR.CO :
* REG-PIPELINE UPDATE FROM BIOPORTO
* EXPECTS TO COMPLETE CLINICAL STUDY AND SUBMIT A DE NOVO
APPLICATION TO FDA FOR PEDIATRIC USE OF NGAL TEST™ THIS SUMMER
* BIOPORTO AWAITS US TEST RESULTS FOR RAPID GRAD-BASED
SARS-COV-2
ASSAY
* IF RESULTS FOR RAPID GRAD-BASED SARS-COV-2 ASSAY IS
POSITIVE,
COMPANY WILL PROCEED TOWARDS EUA AND CE MARK IN Q2 OF 2021
Source text for Eikon: ID:nGNEbbWgy6
Further company coverage: BIOPOR.CO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bioporto A/S
See all news
